// App-Quantinova.ai

319 : The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab

Researchers

Presenter

  • Felicia Cosman

Principal Investigators

  • Daria B Crittenden

  • Serge Ferrari

  • Aliya Khan

  • Nancy E Lane

  • Kurt Lippuner

  • Toshio Matsumoto

  • Cassandra E Milmont

  • Cesar Libanati

  • Andreas Grauer

Medical Centers

  • Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY

  • Amgen Inc, Thousand Oaks, CA

  • Geneva University Hospitals, Geneva, Switzerland

  • McMaster University, Hamilton, ON, Canada

  • UC Davis Medical Center, Sacramento, CA

  • Osteoporosis Policlinic, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

  • The University of Tokushima, Tokushima, Japan.

  • UCB Pharma, Brussels, Belgium

Locations

  • United States

  • Switzerland

  • Canada

  • Japan

  • Belgium

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Romosozumab

  • Denosumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved